Innoviva, Inc. (INVA) Financial Ratios
24 years of historical data (2002–2025) · Healthcare · Biotechnology
EV/EBITDA
↑
7.99
+6% vs avg
5yr avg: 7.51
30Y Low3.9·High39.3
P/FCF
↑
9.76
↑+35% vs avg
5yr avg: 7.23
30Y Low4.5·High120.1
P/B Ratio
↓
1.63
↓-24% vs avg
5yr avg: 2.14
30Y Low1.4·High21.6
ROE
↓
29.1%
-1% vs avg
5yr avg: 29.5%
30Y Low-445%·High248%
Debt/EBITDA
↑
1.32
↓-36% vs avg
5yr avg: 2.08
30Y Low0.9·High16.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
INVA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Innoviva, Inc. trades at 6.8x earnings, 53% below its 5-year average of 14.6x, sitting at the 50th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 69%. On a free-cash-flow basis, the stock trades at 9.8x P/FCF, 35% above the 5-year average of 7.2x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.7B | $1.3B | $1.4B | $1.3B | $1.6B | $1.4B | $1.6B | $2.0B | $1.7B | $1.3B |
| Enterprise Value | $1.6B | $1.4B | $1.4B | $1.6B | $1.5B | $1.8B | $1.5B | $1.7B | $2.3B | $2.2B | $1.9B |
| P/E Ratio → | 6.82 | 6.06 | 48.19 | 7.29 | 5.59 | 6.01 | 6.13 | 9.90 | 4.94 | 12.13 | 20.19 |
| P/S Ratio | 4.49 | 3.99 | 3.59 | 4.49 | 3.81 | 4.15 | 4.18 | 6.15 | 7.58 | 7.83 | 9.87 |
| P/B Ratio | 1.63 | 1.44 | 1.86 | 2.06 | 2.23 | 3.09 | 2.31 | 4.69 | 12.44 | — | — |
| P/FCF | 9.76 | 8.65 | 6.83 | 9.91 | 6.26 | 4.49 | 4.49 | 6.24 | 8.85 | 12.00 | 21.72 |
| P/OCF | 9.70 | 8.60 | 6.82 | 9.88 | 6.26 | 4.47 | 4.49 | 6.24 | 8.85 | 12.00 | 21.62 |
P/E links to full P/E history page with 30-year chart
INVA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Innoviva, Inc.'s enterprise value stands at 8.0x EBITDA, 6% above its 5-year average of 7.5x. The Healthcare sector median is 14.1x, placing the stock at a 44% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.32 | 4.00 | 5.31 | 4.57 | 4.64 | 4.59 | 6.53 | 8.81 | 10.25 | 14.35 |
| EV / EBITDA | 7.99 | 6.92 | 7.44 | 12.15 | 7.13 | 3.92 | 4.15 | 6.55 | 9.12 | 11.27 | 15.59 |
| EV / EBIT | 9.95 | 4.11 | 24.05 | 7.73 | 5.00 | 3.92 | 4.15 | 6.92 | 9.82 | 12.13 | 17.59 |
| EV / FCF | — | 7.21 | 7.61 | 11.72 | 7.51 | 5.02 | 4.94 | 6.62 | 10.29 | 15.71 | 31.57 |
INVA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Innoviva, Inc. earns an operating margin of 38.5%. Operating margins have expanded from 36.7% to 38.5% over the past 3 years, signaling improving operational efficiency. ROE of 29.1% indicates solid capital efficiency. ROIC of 14.2% represents solid returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.3% | 72.3% | 89.8% | 86.3% | 95.8% | 100.0% | 100.0% | 100.0% | 100.0% | 99.4% | 99.0% |
| Operating Margin | 38.5% | 38.5% | 46.5% | 36.7% | 62.5% | 95.7% | 95.3% | 94.4% | 91.3% | 84.5% | 81.6% |
| Net Profit Margin | 63.8% | 63.8% | 6.5% | 57.9% | 64.6% | 67.8% | 66.6% | 60.3% | 151.4% | 61.8% | 44.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 29.1% | 29.1% | 3.4% | 29.0% | 39.2% | 46.9% | 47.2% | 62.8% | 248.4% | — | — |
| ROA | 18.5% | 18.5% | 1.8% | 14.5% | 19.8% | 27.6% | 26.0% | 24.7% | 86.3% | 35.9% | 14.8% |
| ROIC | 14.2% | 14.2% | 14.2% | 9.8% | 20.2% | 38.4% | 40.5% | 40.1% | 46.9% | 52.1% | 34.3% |
| ROCE | 12.4% | 12.4% | 14.7% | 9.9% | 20.5% | 39.2% | 37.5% | 39.0% | 54.5% | 53.1% | 28.3% |
INVA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Innoviva, Inc. carries a Debt/EBITDA ratio of 1.3x, which is manageable (59% below the sector average of 3.3x). The company holds a net cash position — cash of $551M exceeds total debt of $269M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 20.6x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.23 | 0.65 | 0.67 | 0.96 | 0.75 | 0.63 | 1.10 | 2.41 | — | — |
| Debt / EBITDA | 1.32 | 1.32 | 2.34 | 3.31 | 2.56 | 0.85 | 1.03 | 1.45 | 1.52 | 3.03 | 5.82 |
| Net Debt / Equity | — | -0.24 | 0.21 | 0.38 | 0.45 | 0.37 | 0.23 | 0.29 | 2.01 | — | — |
| Net Debt / EBITDA | -1.38 | -1.38 | 0.76 | 1.88 | 1.19 | 0.42 | 0.37 | 0.38 | 1.27 | 2.66 | 4.86 |
| Debt / FCF | — | -1.44 | 0.78 | 1.82 | 1.25 | 0.53 | 0.44 | 0.38 | 1.43 | 3.71 | 9.85 |
| Interest Coverage | 20.57 | 20.57 | 2.68 | 11.13 | 19.17 | 24.35 | 20.32 | 13.20 | 9.78 | 4.21 | 2.08 |
Net cash position: cash ($551M) exceeds total debt ($269M)
INVA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Innoviva, Inc.'s current ratio of 14.64x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 13.85x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 9.03x to 14.64x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.64 | 14.64 | 2.35 | 9.03 | 3.29 | 54.02 | 55.98 | 80.29 | 34.92 | 5.75 | 9.88 |
| Quick Ratio | 13.85 | 13.85 | 2.21 | 7.96 | 2.87 | 54.02 | 55.98 | 80.29 | 34.92 | 5.77 | 9.88 |
| Cash Ratio | 11.09 | 11.09 | 1.75 | 5.07 | 2.16 | 34.70 | 40.34 | 65.32 | 20.16 | 3.72 | 7.50 |
| Asset Turnover | — | 0.26 | 0.28 | 0.25 | 0.27 | 0.42 | 0.34 | 0.36 | 0.48 | 0.59 | 0.35 |
| Inventory Turnover | 3.00 | 3.00 | 1.09 | 1.05 | 0.25 | — | — | — | — | — | — |
| Days Sales Outstanding | — | 30.02 | 87.88 | 98.84 | 70.58 | 103.12 | 101.80 | 111.07 | 116.47 | 118.53 | 128.02 |
INVA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Innoviva, Inc. returns 0.2% to shareholders annually primarily through share buybacks. The earnings yield of 14.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.1% |
| Payout Ratio | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.2% | 1.6% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 14.7% | 16.5% | 2.1% | 13.7% | 17.9% | 16.6% | 16.3% | 10.1% | 20.2% | 8.2% | 5.0% |
| FCF Yield | 10.2% | 11.6% | 14.6% | 10.1% | 16.0% | 22.3% | 22.3% | 16.0% | 11.3% | 8.3% | 4.6% |
| Buyback Yield | 0.2% | 0.3% | 1.2% | 5.4% | 0.7% | 24.2% | 0.0% | 0.0% | 0.2% | 5.9% | 6.0% |
| Total Shareholder Yield | 0.2% | 0.3% | 1.2% | 5.4% | 0.7% | 24.2% | 0.0% | 0.0% | 0.2% | 5.9% | 6.1% |
| Shares Outstanding | — | $85M | $74M | $87M | $95M | $94M | $114M | $113M | $113M | $120M | $123M |
Peer Comparison
Compare INVA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 INVAYou | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRGO | $2B | -1.2 | 7.5 | 11.6 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 GSK | $102B | 6.7 | 8.4 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 AZN | $287B | 28.3 | 16.0 | 24.4 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 TEVA | $42B | 30.3 | 17.8 | 36.9 | 51.8% | 12.5% | 20.7% | 7.7% | 5.5 |
 AMRN | $310M | -8.3 | — | 46.0 | 56.6% | -6.5% | -8.2% | -2.9% | — |
 INCY | $20B | 15.6 | 11.8 | 14.7 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 MRK | $280B | 15.6 | 10.8 | 22.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 PFE | $151B | 19.5 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 CVS | $111B | 62.5 | 13.1 | 14.3 | 13.8% | 2.6% | 2.3% | 5.0% | 6.2 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
See INVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INVA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INVA vs PRGO
Side-by-side business, growth, and profitability comparison vs Perrigo Company plc.
Start ComparisonINVA — Frequently Asked Questions
Quick answers to the most common questions about buying INVA stock.
What is Innoviva, Inc.'s P/E ratio?
Innoviva, Inc.'s current P/E ratio is 6.8x. The historical average is 12.6x. This places it at the 50th percentile of its historical range.
What is Innoviva, Inc.'s EV/EBITDA?
Innoviva, Inc.'s current EV/EBITDA is 8.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.2x.
What is Innoviva, Inc.'s ROE?
Innoviva, Inc.'s return on equity (ROE) is 29.1%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -36.2%.
Is INVA stock overvalued?
Based on historical data, Innoviva, Inc. is trading at a P/E of 6.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Innoviva, Inc.'s profit margins?
Innoviva, Inc. has 72.3% gross margin and 38.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does Innoviva, Inc. have?
Innoviva, Inc.'s Debt/EBITDA ratio is 1.3x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.